UNASSIGNED: Interferon alpha ( @entity3027 ) has been used for over 30 years to treat @entity5 ( @entity5 ). @entity3027 was shown to induce clinical, hematological, molecular and histopathological responses in small clinical studies. Such combined efficacy has never been achieved with any other drug to date in such a significant proportion of @entity1 . However, @entity137 remains a limitation to its broader use despite the development of pegylated forms with better tolerance. Several on going phase 3 studies of peg- @entity3027 versus hydroxyurea will help to define its exact place in MPN management. @entity3027 efficacy is likely the consequence of a broad range of biological properties, including enhancement of immune response, direct effects on malignant cells and ability to cycle dormant malignant stem cells. However, comprehensive elucidation of its mechanism of action is still lacking. Sustained clinical, molecular and morphological responses after @entity3027 discontinuation raised the hope that this drug could eradicate MPN. There is now consistent evidence showing that @entity3027 is able to eliminate malignant clones harboring JAK2V617F or @entity4015 mutations. However, the molecular complexity of these diseases could hamper @entity3027 efficacy, as the presence of additional non-driver mutations, like in the @entity5312 gene, could be associated with resistance to @entity3027 . Therefore, combined therapy with another targeted agent could be required to eradicate MPN, and the best @entity3027 companion for achieving this challenge remains to be determined. @entity1778 advance online publication, 18 December 2015; doi:10.1038/leu.2015.326.

Interferon-alpha for the therapy of XXXX : targeting the malignant clone.

@entity1 :: ('9606', 'Species') :: ['patients'] @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity'] @entity5312 :: ('54790', 'Gene') :: ['TET2'] @entity5 :: ('MESH:D009369', 'Disease') :: ['MPNs', 'myeloproliferative neoplasms'] @entity1778 :: ('MESH:D007938', 'Disease') :: ['Leukemia'] @entity4015 :: ('811', 'Gene') :: ['Calreticulin'] @entity3027 :: ('3439', 'Gene') :: ['IFN-a']
@entity5 :: (MESH:D009369,Disease) :: ['myeloproliferative neoplasms']
